



Bayer AG  
Investor Relations  
51368 Leverkusen  
Germany  
[www.investor.bayer.com](http://www.investor.bayer.com)

## Investor News

**For use outside the US and UK only**

---

### **New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.**

Once approved, the new low dose IUS will offer young women contraception for up to three years

---

**Leverkusen, December 14, 2011** – Bayer HealthCare has submitted an application for marketing authorization in the European Union and in the U.S. for a new low dose levonorgestrel releasing intrauterine system (IUS) for long-term contraception of up to three years. Sweden will serve as the reference member state in the decentralized procedure for gaining marketing authorization in the European Union.

The data from clinical studies, including women from North America, Latin America and several European countries, show that the new intrauterine system is an efficacious contraceptive with a good safety profile.

“Once approved our new low dose intrauterine system will be an excellent choice especially for young women who haven’t had children so far and who are looking for a reliable, convenient contraceptive option with a very low hormonal dose,” said Dr. Flemming Ornskov, Chief Marketing Officer - Strategic Marketing General Medicine at Bayer HealthCare.

The new intrauterine system has a small, flexible T-shaped plastic body that allows the controlled release of levonorgestrel at a low rate (initially 10 µg/day) for up to three years. Compared to oral contraceptives, once approved the new IUS is a reliable contraceptive option for young women that does not require remembering to take a pill every day. It also offers rapid return to a woman’s usual level of fertility after removal.

To learn more about contraception, please visit:  
[www.bayerpharma.de/contraception](http://www.bayerpharma.de/contraception)

## **About Bayer HealthCare**

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries. Find more information at [www.bayerhealthcare.com](http://www.bayerhealthcare.com).

### Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Juergen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Judith Nestmann (+49-214-30-66836)

Dr. Olaf Weber (+49-214-30-33567)

Fabian Klingen (+49-214-30-35426)

Ute Menke (+49-214-30-33021)

### **Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at [www.bayer.com](http://www.bayer.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.